The GLP-1 Telehealth Trust Index: Our July 2026 Ranking Methodology Explained

Trust in the GLP-1 telehealth market shouldn't be based on marketing budgets or social media followers. It should be based on measurable, verifiable standards that reflect what actually matters for patient safety and treatment outcomes. This article explains the methodology behind our provider evaluations — how we assess platforms, what we prioritize, and why.

Why a Trust Methodology Matters

The GLP-1 telehealth market has a trust problem. Patients are choosing providers based on ad placement, influencer endorsements, and pricing alone — none of which tell you anything meaningful about clinical quality or safety. Our evaluation framework exists to provide a structured, transparent alternative: a set of criteria that any patient can apply to any platform, with our assessments serving as a starting point rather than the final word.

We don't rank platforms on a leaderboard or assign numerical scores. Rankings create the illusion of precision in what is ultimately a judgment-based evaluation. Instead, we assess platforms against defined standards and present the evidence for patients to evaluate alongside their individual needs and priorities.

Pillar 1: Clinical Standards (Highest Weight)

Clinical quality is the most important evaluation dimension because it directly affects patient safety and treatment outcomes. We assess:

• Prescriber qualifications: Are providers board-certified in relevant specialties (obesity medicine, endocrinology, internal medicine)? Are licenses active and unrestricted? Is provider identity transparent to patients?
• Evaluation thoroughness: Does the platform conduct a genuine clinical evaluation (medical history, contraindication screening, baseline labs) or does it rely on minimal questionnaires?
• Follow-up protocols: Are follow-ups structured and regular (monthly during titration, quarterly during maintenance), or is the platform essentially a prescription-on-demand service?
• Adverse event handling: Does the platform have documented protocols for serious side effects, including clinical triage, MedWatch reporting, and patient follow-up?
• Lab work requirements: Does the platform require and review baseline and monitoring lab work?

Pillar 2: Pharmacy Quality

The quality of the medication you receive is only as good as the pharmacy that prepares it. We evaluate:

• Pharmacy identification: Does the platform disclose which pharmacy compounds or dispenses its medications?
• Regulatory status: Is the pharmacy licensed, accredited (PCAB), and operating as a 503A or 503B facility?
• Quality assurance: Does the pharmacy conduct sterility and potency testing on compounded products?
• FDA compliance history: Has the pharmacy received warning letters or been subject to enforcement actions?

Pillar 3: Transparency and Pricing

Transparency reflects a platform's respect for its patients' intelligence and autonomy:

• Pricing clarity: Are all costs (consultation, medication, shipping, follow-up visits) published before enrollment?
• Compounding disclosure: If medications are compounded, is this clearly communicated with appropriate context about what that means?
• Cancellation and refund policies: Are these clearly stated and fair?
• Informed consent quality: Does the consent process cover risks, benefits, alternatives, and compounding status thoroughly?

Pillar 4: Patient Experience

While less critical than clinical safety, patient experience matters for treatment adherence and satisfaction:

• Provider accessibility: Can patients reach their clinical team between scheduled visits?
• Communication quality: Response times, clarity of communication, continuity of care (seeing the same provider vs. rotating pool)
• Technology usability: Platform ease of use, appointment scheduling, prescription tracking
• Independent patient reviews: What does unfiltered patient feedback from independent sources reveal?

Pillar 5: Regulatory Compliance

The regulatory foundation on which a platform operates affects its longevity and trustworthiness:

• State licensing compliance: Does the platform operate legally in every state where it serves patients?
• HIPAA compliance: Does the platform protect patient data in accordance with federal privacy requirements?
• LegitScript verification: Has the platform undergone independent third-party regulatory verification?
• Adverse event reporting: Does the platform comply with MedWatch reporting obligations?

What We Don't Evaluate

Transparency also means being clear about what falls outside our assessment:

• Marketing claims: We evaluate what platforms do, not what they say they do
• Celebrity endorsements: Endorsements tell you about marketing budgets, not clinical quality
• Social media presence: Follower counts have no correlation with patient safety
• Price as a standalone metric: The cheapest option isn't the best, and the most expensive isn't either